A rapid health technology assessment of apalutamide for the treatment of metastatic castration-sensitive prostate cancer
Objective:To evaluate the effectiveness,safety and economy of apalutamide in the patients with metastatic castration-sensitive prostate cancer(mCSPC),and provide evidence for clinical practice and decision makers.Methods:The Chinese and English databases including PubMed,Embase,the Cochrane Library,CNKI,Wanfang,as well as official website of HTA related agencies for health economic studies targeting mCSPC were searched.Two reviewers independently identified literatures,extracted data and assessed the quality based on inclusion and exclusion criteria.Results:Finally,a total of 3 HTA reports,16 SR/Meta-analysis and 4 pharmacoeconomic studies were screened and included.The results showed that compared with ADT alone,the combination of apalutamide significantly prolonged progression-free survival and overall survival in patients with mCSPC.The efficacy is superior to the combination of cytotoxic docetaxel,comparable to that of other second generation androgen receptor antagonists(SG-ARAs).Apalutamide is well tolerated with no significant increase in serious adverse reactions compared to the control group,thus is a safe variety in the SG-ARAs.Additionally,the included pharmacoeconomic studies showed that apalutamide can prolong quality-adjusted life-years(QALYs),but it has no economic advantage compared with other treatment options.Conclusion:Apalutamide is effective and safe in the treatment of mCSPC.Further health economic evaluation is still needed based on domestic research data.
apalutamidemetastatic castration-sensitive prostate cancerrapid health technology assessment
NETL
NSTL
万方数据
